Immunovant, Inc.
IMVTNASDAQHealthcare● Active
$30.97
$-0.14(-0.45%)
Market Cap$6.4B
P/E Ratio—
52W High$36.285
52W Low$14.32
Immunovant, Inc. (IMVT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IMVT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.46B | $0.36B | $0.21B | $0.16B | $0.10B |
| G&A Expenses | $0.08B | $0.08B | $0.06B | $0.05B | $0.05B |
| Total Operating Expenses | $0.53B | $0.44B | $0.27B | $0.21B | $0.16B |
| Operating Income | ($0.53B) | ($0.44B) | ($0.27B) | ($0.21B) | ($0.16B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.03B | $0.02B | $0.02B | $0.01B | — |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.01B | — |
| Income Before Tax | ($0.51B) | ($0.41B) | ($0.26B) | ($0.21B) | ($0.16B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Net Income | ($0.51B) | ($0.41B) | ($0.26B) | ($0.21B) | ($0.16B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 |
| Wtd Avg Shares | 0.18B | 0.15B | 0.14B | 0.12B | 0.11B |
| EBITDA | ($0.53B) | ($0.44B) | ($0.27B) | ($0.21B) | ($0.16B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Immunovant, Inc. data
About Immunovant, Inc. (IMVT) Income Statement
Immunovant, Inc. (IMVT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, IMVT reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.51B) — a net profit margin of —.
Frequently asked questions
IMVT · 4 questionsImmunovant, Inc. (IMVT) reported revenue of $0.00B for 2026, down —% year-over-year.
IMVT revenueIMVT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08